CN103571872A - 一种能够表达人抗体的转基因动物的制备方法 - Google Patents
一种能够表达人抗体的转基因动物的制备方法 Download PDFInfo
- Publication number
- CN103571872A CN103571872A CN201210281415.1A CN201210281415A CN103571872A CN 103571872 A CN103571872 A CN 103571872A CN 201210281415 A CN201210281415 A CN 201210281415A CN 103571872 A CN103571872 A CN 103571872A
- Authority
- CN
- China
- Prior art keywords
- mouse
- light chain
- locus
- people
- human antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 241001465754 Metazoa Species 0.000 title description 58
- 230000009261 transgenic effect Effects 0.000 title description 31
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 120
- 239000012634 fragment Substances 0.000 claims abstract description 89
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 29
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 29
- 238000011830 transgenic mouse model Methods 0.000 claims abstract description 22
- 230000008707 rearrangement Effects 0.000 claims abstract description 16
- 238000009396 hybridization Methods 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims description 50
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 38
- 210000004436 artificial bacterial chromosome Anatomy 0.000 claims description 32
- 241000699660 Mus musculus Species 0.000 claims description 20
- 238000012239 gene modification Methods 0.000 claims description 20
- 230000005017 genetic modification Effects 0.000 claims description 20
- 235000013617 genetically modified food Nutrition 0.000 claims description 20
- 210000001161 mammalian embryo Anatomy 0.000 claims description 10
- 238000000520 microinjection Methods 0.000 claims description 8
- 230000002779 inactivation Effects 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 230000008676 import Effects 0.000 claims description 5
- 210000000130 stem cell Anatomy 0.000 claims description 4
- 230000006698 induction Effects 0.000 claims description 3
- 238000001890 transfection Methods 0.000 claims description 3
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 abstract description 28
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 102000053602 DNA Human genes 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 description 36
- 108700019146 Transgenes Proteins 0.000 description 24
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 22
- 210000003719 b-lymphocyte Anatomy 0.000 description 19
- 101150117115 V gene Proteins 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 14
- 241000124008 Mammalia Species 0.000 description 8
- 230000006801 homologous recombination Effects 0.000 description 8
- 238000002744 homologous recombination Methods 0.000 description 8
- 101150008942 J gene Proteins 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 230000010354 integration Effects 0.000 description 7
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 6
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 6
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 6
- 210000001671 embryonic stem cell Anatomy 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000006062 fragmentation reaction Methods 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 238000013016 damping Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 210000004681 ovum Anatomy 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 4
- 101150097493 D gene Proteins 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 208000033040 Somatoform disorder pregnancy Diseases 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000013011 mating Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 229940049547 paraxin Drugs 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- -1 polyoxyethylene Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 241000585705 Alicia <angiosperm> Species 0.000 description 1
- 101100111164 Arabidopsis thaliana BAC2 gene Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241001214789 Basilea Species 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010042573 Superovulation Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 108700022109 ropocamptide Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210281415.1A CN103571872B (zh) | 2012-08-09 | 2012-08-09 | 一种能够表达人抗体的转基因动物的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210281415.1A CN103571872B (zh) | 2012-08-09 | 2012-08-09 | 一种能够表达人抗体的转基因动物的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103571872A true CN103571872A (zh) | 2014-02-12 |
CN103571872B CN103571872B (zh) | 2016-11-23 |
Family
ID=50044583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210281415.1A Active CN103571872B (zh) | 2012-08-09 | 2012-08-09 | 一种能够表达人抗体的转基因动物的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103571872B (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105441455A (zh) * | 2015-10-21 | 2016-03-30 | 重庆市畜牧科学院 | 一种嵌合核酸分子及其在人源化抗体制备中的应用 |
CN105777894A (zh) * | 2016-03-12 | 2016-07-20 | 长春力太生物技术有限公司 | 通过转基因啮齿类动物制备人源化驼类单域抗体的方法 |
CN109280674A (zh) * | 2017-07-21 | 2019-01-29 | 北京百奥赛图基因生物技术有限公司 | 一种筛选抗体的非人模式动物的构建方法及其应用 |
WO2020169022A1 (en) * | 2019-02-18 | 2020-08-27 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animals with humanized immunoglobulin locus |
WO2020239005A1 (zh) | 2019-05-30 | 2020-12-03 | 山东博安生物技术有限公司 | 靶向Claudin18.2的抗体或嵌合抗原受体 |
WO2020248938A1 (zh) | 2019-06-10 | 2020-12-17 | 山东博安生物技术有限公司 | 抗cd25抗体及其应用 |
WO2020248926A1 (zh) | 2019-06-10 | 2020-12-17 | 山东博安生物技术有限公司 | 抗PDL1和TGFβ的双功能融合蛋白及其用途 |
WO2021261620A1 (ko) * | 2020-06-25 | 2021-12-30 | 주식회사 휴맵 | 이형접합성 형질전환 동물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101002549A (zh) * | 1995-10-10 | 2007-07-25 | 真药物国际公司 | 能够生产异源抗体的转基因非人动物 |
EP2294917A1 (en) * | 2001-03-22 | 2011-03-16 | Abbott GmbH & Co. KG | Transgenic animals expressing antibodies specific for genes of interest and uses thereof |
CN102123582A (zh) * | 2008-06-27 | 2011-07-13 | 莫鲁斯有限公司 | 产生抗体的非人哺乳动物 |
CN102292445A (zh) * | 2008-12-18 | 2011-12-21 | 伊拉兹马斯大学鹿特丹医学中心 | 表达人源化抗体的非人转基因动物及其用途 |
-
2012
- 2012-08-09 CN CN201210281415.1A patent/CN103571872B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101002549A (zh) * | 1995-10-10 | 2007-07-25 | 真药物国际公司 | 能够生产异源抗体的转基因非人动物 |
EP2294917A1 (en) * | 2001-03-22 | 2011-03-16 | Abbott GmbH & Co. KG | Transgenic animals expressing antibodies specific for genes of interest and uses thereof |
US20110154521A1 (en) * | 2001-03-22 | 2011-06-23 | Abbott Laboratories | Transgenic animals expressing antibodies specific for genes of interest and uses thereof |
CN102123582A (zh) * | 2008-06-27 | 2011-07-13 | 莫鲁斯有限公司 | 产生抗体的非人哺乳动物 |
CN102292445A (zh) * | 2008-12-18 | 2011-12-21 | 伊拉兹马斯大学鹿特丹医学中心 | 表达人源化抗体的非人转基因动物及其用途 |
Non-Patent Citations (4)
Title |
---|
KAZUMA TOMIZUKA ET.AL.,: "Double trans-chromosomic mice: Maintenance of two individual human chromosome fragments containing Ig heavy and k loci and expression of fully human antibodies", 《PNAS》 * |
KYMOUSE: "Next Generation In Vivo Human Antibody Platform", 《NON CONFIDENTIAL PARTNERING PRESENTATION》 * |
STEPHEN HANSEN: "Kymab: More mAb diversity", 《BIOCENTURY》 * |
林芸等: "人源化抗体研究历程及发展趋势", 《生物工程学报》 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105441455A (zh) * | 2015-10-21 | 2016-03-30 | 重庆市畜牧科学院 | 一种嵌合核酸分子及其在人源化抗体制备中的应用 |
CN105441455B (zh) * | 2015-10-21 | 2020-08-28 | 重庆金迈博生物科技有限公司 | 一种嵌合核酸分子及其在人源化抗体制备中的应用 |
CN105777894A (zh) * | 2016-03-12 | 2016-07-20 | 长春力太生物技术有限公司 | 通过转基因啮齿类动物制备人源化驼类单域抗体的方法 |
CN109280674A (zh) * | 2017-07-21 | 2019-01-29 | 北京百奥赛图基因生物技术有限公司 | 一种筛选抗体的非人模式动物的构建方法及其应用 |
CN109280674B (zh) * | 2017-07-21 | 2020-12-01 | 北京百奥赛图基因生物技术有限公司 | 一种筛选抗体的非人模式动物的构建方法及其应用 |
WO2020169022A1 (en) * | 2019-02-18 | 2020-08-27 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animals with humanized immunoglobulin locus |
US11730151B2 (en) | 2019-02-18 | 2023-08-22 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with humanized immunoglobulin locus |
WO2020239005A1 (zh) | 2019-05-30 | 2020-12-03 | 山东博安生物技术有限公司 | 靶向Claudin18.2的抗体或嵌合抗原受体 |
WO2020248938A1 (zh) | 2019-06-10 | 2020-12-17 | 山东博安生物技术有限公司 | 抗cd25抗体及其应用 |
WO2020248926A1 (zh) | 2019-06-10 | 2020-12-17 | 山东博安生物技术有限公司 | 抗PDL1和TGFβ的双功能融合蛋白及其用途 |
WO2021261620A1 (ko) * | 2020-06-25 | 2021-12-30 | 주식회사 휴맵 | 이형접합성 형질전환 동물 |
Also Published As
Publication number | Publication date |
---|---|
CN103571872B (zh) | 2016-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103571872A (zh) | 一种能够表达人抗体的转基因动物的制备方法 | |
CN102719444B (zh) | 人或人源化免疫球蛋白在非人转基因动物中增强的表达 | |
CN103917650B (zh) | 人源化的通用轻链小鼠 | |
KR101481843B1 (ko) | 형질전환 동물 내에서의 중쇄만의 항체의 생성 | |
JP6073550B2 (ja) | 遺伝子操作した動物から得られるヒトポリクローナル抗体 | |
JP2020078350A (ja) | ヒスチジン操作軽鎖抗体およびそれを生成するための遺伝子改変非ヒト動物 | |
CA2634294A1 (en) | Production of humanized antibodies in transgenic animals | |
JP2001527386A (ja) | 異種抗体を産生し得るトランスジェニック非ヒト動物 | |
WO2022166802A1 (zh) | 抗人cd271的单克隆抗体及用途 | |
CN117099741A (zh) | 具有人源化免疫球蛋白基因座的经遗传修饰的非人动物 | |
EP3770261B1 (en) | Nucleic acid molecule and application thereof in preparing human single-domain antibody | |
CN105777894A (zh) | 通过转基因啮齿类动物制备人源化驼类单域抗体的方法 | |
CN101595128A (zh) | 免疫应答增强的转基因动物和用于制备其的方法 | |
US9476027B2 (en) | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals | |
WO2017067043A1 (zh) | 一种嵌合核酸分子及其在人源化抗体制备中的应用 | |
WO2017067042A1 (zh) | 一种制备人源化抗体的核酸分子及其应用 | |
Mompó et al. | Antigen-specific human monoclonal antibodies from transgenic mice | |
CN102333874A (zh) | 具有增强的免疫球蛋白重链类别转换至Cε的高IgE动物模型 | |
CN101886082B (zh) | 利用动物乳腺生物反应器生产人源化单克隆抗体的方法 | |
Lim et al. | Production of anti-phosphorylcholine antibodies of the T15 idiotype in CBA/N xid mice: investigation of the defect using a T15 immunoglobulin transgene | |
JP2021512651A (ja) | 核酸分子およびヒト化抗体における核酸分子の応用 | |
CN102850452B (zh) | 用于抑制内源性免疫球蛋白基因和生产转基因人独特型抗体的组合物和方法 | |
Duteau | Characterization of the human Ig guest locus in HAC transgenic cattle | |
EP1604997A1 (en) | Human polyclonal antibodies from transgenic nonhuman animals | |
Choi | Fully human antigen-specific polyclonal antibody responses induced in cloned human artificial chromosome transchromosomic cattle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: LVYE INVESTMENT GROUP CO., LTD. Effective date: 20140731 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20140731 Address after: 264670 high tech Zone, Shandong, Yantai science and technology Avenue, No. 39 Applicant after: Shandong International Biotechnology Park Development Co., Ltd. Applicant after: Lvye Investment Group Co., Ltd. Address before: 264670 high tech Zone, Shandong, Yantai science and technology Avenue, No. 39 Applicant before: Shandong International Biotechnology Park Development Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CB02 | Change of applicant information |
Inventor after: Feng Dongxiao Inventor after: Xu Dongxue Inventor after: Gao Yan Inventor after: Li Bing Inventor after: Zhang Shumin Inventor after: Yang Xiaoping Inventor after: Dai Jie Inventor after: Zhang Hui Inventor after: Xu Conglun Inventor after: Dong Chuangchuang Inventor after: Liu Hong Inventor after: Zhao Ming Inventor before: Feng Dongxiao Inventor before: Dai Jie Inventor before: Zhang Hui Inventor before: Xu Conglun Inventor before: Dong Chuangchuang Inventor before: Liu Hong |
|
CB03 | Change of inventor or designer information | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190930 Address after: 264670 No. 39, science and technology Avenue, hi tech Zone, Shandong, Yantai Co-patentee after: SHANDONG BIOANTY BIOLOGICAL TECHNOLOGY CO., LTD. Patentee after: Shandong International Biotechnology Park Development Co., Ltd. Address before: 264670 No. 39, science and technology Avenue, hi tech Zone, Shandong, Yantai Co-patentee before: Lvye Investment Group Co., Ltd. Patentee before: Shandong International Biotechnology Park Development Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201027 Address after: 264670 No. 39, science and technology Avenue, hi tech Zone, Shandong, Yantai Patentee after: SHANDONG BIOANTY BIOLOGICAL TECHNOLOGY Co.,Ltd. Address before: 264670 No. 39, science and technology Avenue, hi tech Zone, Shandong, Yantai Patentee before: SHANDONG INTERNATIONAL BIOTECHNOLOGY PARK DEVELOPMENT Co.,Ltd. Patentee before: SHANDONG BIOANTY BIOLOGICAL TECHNOLOGY Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 264670 No. 39 Science and Technology Avenue, Yantai High-tech Zone, Shandong Province Patentee after: Shandong Boan Biotechnology Co.,Ltd. Address before: 264670 No. 39 Science and Technology Avenue, Yantai High-tech Zone, Shandong Province Patentee before: SHANDONG BIOANTY BIOLOGICAL TECHNOLOGY Co.,Ltd. |